Yoshii K, Seki Y, Aiba T, Tsukada T, Shiozawa R
No To Shinkei. 1985 Oct;37(10):985-90.
Anti-platelet therapy (Aspirin 250 mg/every other day approximately 1000 mg/day + Dipyridamole 150 mg/day) was performed on 51 patients with ischemic cerebrovascular disorders (ICVD). Among these patients, 41 cases showed no recurrence of ICVD attack, whereas the remaining 10 cases had re-attacks. These 2 groups were compared from the viewpoint of various risk factors and other clinical findings: e.g. CT scan and angiographic appearance. But there was no statistically significant difference between them. Platelet aggregability and platelet survival time were examined in twenty-eight patients out of cases. We used a simple nonradioisotope technic for the determination of platelet survival time. Platelet survival time was shortened in 22 of 28 (79%) patients. On the other hand, platelet aggregability was found to have no definite tendency. In 9 of 10 cases, platelet survival time was revealed to be prolonged several months after administration of anti-platelet drugs. There was no re-attack in 7 of these 9 patients. Some reports also showed that platelet survival time was shortened in various thromboembolism and recovered by anti-platelet drugs. Measurement of platelet survival time is thought to be an important method as to the indication and the monitoring of anti-platelet therapy.
对51例缺血性脑血管疾病（ICVD）患者进行了抗血小板治疗（阿司匹林250mg/隔日，约1000mg/天+双嘧达莫150mg/天）。在这些患者中，41例未出现ICVD发作复发，而其余10例有再次发作。从各种危险因素和其他临床检查结果（如CT扫描和血管造影表现）的角度对这两组进行了比较。但两组之间无统计学显著差异。对其中28例患者检测了血小板聚集性和血小板存活时间。我们采用一种简单的非放射性技术测定血小板存活时间。28例患者中有22例（79%）血小板存活时间缩短。另一方面，血小板聚集性未发现明确的倾向。10例中有9例在使用抗血小板药物后血小板存活时间延长了数月。这9例患者中有7例未再次发作。一些报告还显示，在各种血栓栓塞中血小板存活时间缩短，且抗血小板药物可使其恢复。血小板存活时间的测定被认为是抗血小板治疗的指征和监测的重要方法。
